User:Mr. Ibrahem/Esmolol

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Esmolol
Clinical data
AHFS/Drugs.comMonograph
Pregnancy
category
  • AU: C
Routes of
administration		Intravenous[1]
Drug classCardioselective beta1 receptor blocker
Pharmacokinetic data
Bioavailability-
Protein binding60%
MetabolismErythrocytic
Onset of actionWithin a min[1]
Elimination half-life9 minutes[2]
Duration of actionUp to 30 min[1]
ExcretionKidney
Identifiers
  • methyl (RS)-3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate
Chemical and physical data
FormulaC16H25NO4
Molar mass295.379 g·mol−1
3D model (JSmol)
  • O=C(OC)CCc1ccc(OCC(O)CNC(C)C)cc1
  • InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3 checkY
  • Key:AQNDDEOPVVGCPG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Esmolol, sold under the brand name Brevibloc among others, is a medication used to treat supraventricular arrhythmias, high blood pressure, and myocardial ischemia.[1] It is given by injection into a vein.[1] Onset of effects can begin within a minute and last for up to 30 minutes.[1]

Common side effects include low blood pressure, sweating, headache, nausea, and inflammation at the site of injection.[1] Other side effects may include swelling, pulmonary edema, and urinary retention.[3] It is a cardioselective beta1 receptor blocker which inhibits the sympathetic nervous system.[4][5] It is a class II antiarrhythmic.[6]

Esmolol was patented in 1980 and approved for medical use in 1986.[7][1] It is available as a generic medication.[3] In the United Kingdom it costs the NHS about £10 per 100 mg vial.[3] In the United States this amount is about 6 USD as of 2021.[8]

References[edit]

  1. ^ a b c d e f g h i j "Esmolol Monograph for Professionals". Drugs.com. Archived from the original on 24 January 2021. Retrieved 23 July 2021.
  2. ^ Benowitz, Neal L. (2020). "11. Antihypertensive agents". In Katzung, Bertram G.; Trevor, Anthony J. (eds.). Basic and Clinical Pharmacology (15th ed.). New York: McGraw-Hill. p. 193. ISBN 978-1-260-45231-0. Archived from the original on 2021-10-10. Retrieved 2021-12-05.
  3. ^ a b c d BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 166. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  4. ^ Barash, Paul G.; Cullen, Bruce F.; Stoelting, Robert K.; Cahalan, Michael; Stock, M. Christine (1 January 2011). Clinical Anesthesia. Lippincott Williams & Wilkins. p. PT1598. ISBN 978-1-4511-2297-8. Archived from the original on 28 August 2021. Retrieved 23 July 2021.
  5. ^ Sharar, Sam R.; Cullen, Bruce F.; Stock, Christine M.; Ortega, Rafael; Holt, Natalie; Nathan, Naveen; Connor, Christopher (9 July 2021). Clinical Anesthesia Fundamentals. Lippincott Williams & Wilkins. p. PT335. ISBN 978-1-9751-1302-5. Archived from the original on 28 August 2021. Retrieved 23 July 2021.
  6. ^ Marx, John; Hockberger, Robert; Walls, Ron (1 August 2013). Rosen's Emergency Medicine - Concepts and Clinical Practice E-Book: 2-Volume Set. Elsevier Health Sciences. p. 1038. ISBN 978-1-4557-4987-4. Archived from the original on 28 August 2021. Retrieved 23 July 2021.
  7. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 462. ISBN 978-3-527-60749-5. Archived from the original on 2021-06-10. Retrieved 2021-03-18.
  8. ^ "Esmolol Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 28 August 2021. Retrieved 23 July 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Esmolol&oldid=1205207983"